Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan V Boddy

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2009
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastomaRachel A Daniel, Agata L Rozanska, Huw D Thomas, et al.
Pediatric Blood & Cancer|December 27, 2019
Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemiaJinhan Xie, Miriam Span, Erik van Maarseveen, et al.
Molecular Cancer Therapeutics|October 7, 2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous SystemKaren E Parrish, Ling Cen, James Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumorsRuth Plummer, Laura Vidal, Melanie Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group StudyGareth J Veal, Michael Cole, Julie Errington, et al.
Blood Advances|January 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APLHarry J Iland, John Reynolds, Alan V Boddy, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2016
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumoursDavid Jamieson, Melanie J Griffin, Julieann Sludden, et al.
The Australian and New Zealand Journal of Psychiatry|November 19, 2019
Wnt receptor gene <i>FZD1</i> was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohortXiaoman Liu, Siew-Kee Low, Joshua R Atkins, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2009
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastomaRachel A Daniel, Agata L Rozanska, Huw D Thomas, et al.
Pediatric Blood & Cancer|December 27, 2019
Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemiaJinhan Xie, Miriam Span, Erik van Maarseveen, et al.
Molecular Cancer Therapeutics|October 7, 2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous SystemKaren E Parrish, Ling Cen, James Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumorsRuth Plummer, Laura Vidal, Melanie Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group StudyGareth J Veal, Michael Cole, Julie Errington, et al.
Blood Advances|January 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APLHarry J Iland, John Reynolds, Alan V Boddy, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2016
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumoursDavid Jamieson, Melanie J Griffin, Julieann Sludden, et al.
The Australian and New Zealand Journal of Psychiatry|November 19, 2019
Wnt receptor gene <i>FZD1</i> was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohortXiaoman Liu, Siew-Kee Low, Joshua R Atkins, et al.
Pageof 9